Research programme: non-nucleoside hepatitis C antivirals - BioWest
Latest Information Update: 27 Jun 2012
At a glance
- Originator MIGENIX
- Class Small molecules
- Mechanism of Action Hepatitis B virus replication inhibitors; Hepatitis C virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis B; Hepatitis C
Most Recent Events
- 19 Aug 2011 Discontinued - Preclinical for Hepatitis C in Canada (PO)
- 08 Jun 2007 Preclinical development is ongoing
- 18 Apr 2006 This programme is still in active development